Nile Pharmaceuticals results, Q1 2022
Net profit, assets, equity and cash flow for Q1 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit18.72 millionEGP
Total assets747 millionEGP
Shareholders' equity390 millionEGP
Operating cash flow6.73 millionEGP
In short
- Nile Pharmaceuticals's net profit for Q1 2022 was about 18.72 million EGP.
- Total assets at the end of Q1 2022 were about 747 million EGP, and shareholders' equity about 390 million EGP.
- Operating cash flow for Q1 2022 was positive at 6.73 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit18.72 million——
Gross profit51.37 million——
Total assets747 million——
Total liabilities357 million——
Shareholders' equity390 million——
Total liabilities and equity747 million——
Operating cash flow6.73 million——
Investing cash flow-32.72 million——
Financing cash flow33.95 million——
Net change in cash7.95 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy